Paul Tudor Jones’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Paul Tudor Jones’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-83,891	Closed	-$2M	–	1462
2019 Q4	$2M	Buy	83,891 +1,103	+1%	+$30.4K	0.09%	283
2019 Q3	$2.22M	Buy	82,788 +19,043	+30%	+$535K	0.08%	286
2019 Q2	$1.73M	Buy	+63,745	New	+$2M	0.05%	378
2018 Q1	–	Sell	-7,580	Closed	-$369K	–	1356
2017 Q4	$369K	Sell	7,580 -24,381	-76%	-$1.23M	0.01%	725
2017 Q3	$1.73M	Buy	31,961 +15,542	+95%	+$912K	0.04%	244
2017 Q2	$922K	Buy	+16,419	New	+$658K	0.03%	371
2016 Q3	–	Sell	-24,761	Closed	-$584K	–	1830
2016 Q2	$584K	Sell	24,761 -5,681	-19%	-$140K	0.01%	734
2016 Q1	$621K	Buy	30,442 +5,901	+24%	+$187K	0.02%	810
2015 Q4	$1.26M	Buy	24,541 +12,327	+101%	+$598K	0.04%	358
2015 Q3	$521K	Buy	+12,214	New	+$589K	0.02%	760
2015 Q2	–	Sell	-6,016	Closed	-$228K	–	1744
2015 Q1	$228K	Buy	+6,016	New	+$207K	0.01%	1225

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Paul Tudor Jones's PTLA Position: Q1 2020 in Review

Paul Tudor Jones sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 83,891 shares — an estimated $2M sold.

Paul Tudor Jones first reported a position in PTLA in Q1 2015 and held it in 11 quarters. The position peaked at $2.22M in Q3 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Paul Tudor Jones reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Paul Tudor Jones sold 83,891 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $2M.
Paul Tudor Jones first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 11 quarters.
Paul Tudor Jones's Portola Pharmaceuticals, Inc. position peaked at $2.22M in Q3 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Tudor Investment Corp's 13F filing for Q1 2020, filed 15 May 2020.